Politico December 8, 2023
Carmen Paun, Erin Schumaker, Evan Peng, Daniel Payne and Ruth Reader

Pharmaceutical companies and medical device manufacturers expect artificial intelligence to have a profound impact on their businesses next year and are already experimenting with it, according to a Deloitte Center for Health Solutions survey of some 120 executives.

Drug and device makers are exploring how advanced AI could automate repetitive functions, reimagine supply chains and support compliance and regulatory affairs, according to Deloitte.

Who’s in charge? About a quarter of the pharma executives responding to the survey said they have established governance and oversight for AI and another half said they were expecting to do it over the next year.

Medical device manufacturers are slightly behind: One in 5 respondents from the industry said they have a governance and oversight...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Medical Devices, Pharma, Pharma / Biotech, Technology
How our genome is like a generative AI model
Can Pfizer, Sangamo energise haemophilia A gene therapy?
Contributed Content: 2 Alternatives to Ineffective Prescription Drug Rebates
Pharma Pulse 7/25/24: Driving CAR-Ts for Treatment in Cancer and Immunology, CrowdStrike Explains What Went Wrong in Global Outage & more
Roche says it’ll move quickly with ‘differentiated’ obesity drugs

Share This Article